Literature DB >> 3262668

Tryptophan degradation in transplanted tumor cells undergoing rejection.

R Yoshida1, S W Park, H Yasui, O Takikawa.   

Abstract

The depletion of an essential amino acid, tryptophan, caused by indoleamine 2,3-dioxygenase induction in vitro, has been shown to be due to a mechanism that is used in self-defense against inhaled microorganisms and tumor growth. In this communication, we report the results of measuring dioxygenase activity in the peritoneal exudate cells and tumor cytotoxicity at the transplantation loci after in vivo transplantation of tumor cells into the peritoneal cavity of syngeneic or allogeneic strains of mice. The enzyme was induced only when the tumor cells were being rejected from allogeneic animals and no change was observed when the cells continued to grow in syngeneic animals. Furthermore, when the syngeneic tumor cells in a diffusion chamber were i.p. transplanted simultaneously with i.p. injection of allogeneic tumor cells, the enzyme was induced not only in allografted tumor cells but also in the syngeneic tumor cells. Under these conditions, the tumor cells in the diffusion chamber ceased to grow and 50% of the cells were rejected. To determine the type of cells containing the induced enzyme, the peritoneal exudate cells (tumor cells and host cells--mostly small lymphocytes) were separated into six fractions by sedimentation under gravity and by differential centrifugation. Approximately 80% of total enzyme activity was localized in a tumor-rich fraction (98.9% purity), whereas only 0.2% of the activity was found in a lymphocyte-rich fraction (99.5% purity). The localization of indoleamine 2,3-dioxygenase in the tumor cells was confirmed by complement-dependent lysis with specific antibodies against tumor and host cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262668

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Down-regulated expression of monocyte/macrophage major histocompatibility complex receptors in human and mouse monocytes by expression of their ligands.

Authors:  H Yamana; J Tashiro-Yamaji; M Hayashi; S Maeda; T Shimizu; N Tanigawa; K Uchiyama; T Kubota; R Yoshida
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 2.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Catherine Sautès-Fridman; Eric Tartour; Eugene P Kennedy; Michael Platten; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

3.  Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases.

Authors:  S Christen; E Peterhans; R Stocker
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

Review 4.  Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

Authors:  Stefan Löb; Alfred Königsrainer; Hans-Georg Rammensee; Gerhard Opelz; Peter Terness
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

5.  Mononuclear phagocytes: a major population of effector cells responsible for rejection of allografted tumor cells in mice.

Authors:  R Yoshida; O Takikawa; T Oku; A Habara-Ohkubo
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

6.  The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.

Authors:  Christiane A Opitz; Ulrike M Litzenburger; Uta Opitz; Felix Sahm; Katharina Ochs; Christian Lutz; Wolfgang Wick; Michael Platten
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

7.  Blood supply--susceptible formation of melanin pigment in hair bulb melanocytes of mice.

Authors:  Shogo Maeda; Koichi Ueda; Hidenori Yamana; Junko Tashiro-Yamaji; Minenori Ibata; Ayako Mikura; Masashi Okada; Emi Yasuda; Yuro Shibayama; Miya Yoshino; Takahiro Kubota; Ryotaro Yoshida
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-04-07

Review 8.  Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase.

Authors:  Kashif Asghar; Asim Farooq; Bilal Zulfiqar; Asif Loya
Journal:  World J Clin Oncol       Date:  2021-06-24

9.  Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.

Authors:  Derek A Wainwright; Mahua Dey; Alan Chang; Maciej S Lesniak
Journal:  Front Immunol       Date:  2013-05-15       Impact factor: 7.561

10.  A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter.

Authors:  G Melillo; T Musso; A Sica; L S Taylor; G W Cox; L Varesio
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.